My watch list  

40 Current news of CureVac


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
CureVac Streamlines European Network for mRNA Product Manufacturing

Contracts with manufacturing partners WACKER and Celonic terminated


CureVac N.V. announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines following the first wave of the pandemic vaccination ...


image description
CureVac’s Second-Generation Vaccine Candidate Demonstrates Improved Immune Response and Protection

The optimized mRNA backbone has the potential for a multivalent or combination approach to address multiple emerging variants in one vaccine


CureVac N.V. and GSK announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates. The ...


image description
CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation


CureVac N.V. announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases. The DSMB confirmed that ...


image description
Second-Generation COVID-19 Vaccine Candidate Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

Fast onset of strong neutralizing antibody titers after first vaccination


CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. ...


image description
CureVac’s COVID-19 Vaccine Candidate Demonstrates Protection Against South African Variant in Preclinical Challenge Study

Full protection of immunized mice from infection and mortality during variant challenge infection


CureVac N.V. announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 (also referred to as the “South African” variant) and a strain of the original SARS-CoV-2 B1 ...


image description
CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses

Impact of new SARS-CoV-2 variants supports specification of select strains for anticipated case-driven interim analysis in pivotal Phase 2b/3 study


CureVac N.V. announced plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being evaluated in the pivotal HERALD Phase 2b/3 trial in Europe and Latin America. Rapid distribution of ...


image description
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

Anticipated production of up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022 at the Novartis’ manufacturing site in Kundl, Austria


CureVac N.V. and Novartis AG announced that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. Following final agreement, Novartis plans to ...


image description
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate

Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV


CureVac N.V. announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company’s mRNA-based COVID-19 vaccine candidate, currently in late-stage clinical testing. The process was initiated when the first data package consisting of CVnCoV pre-clinical ...


image description
GSK and CureVac to develop next generation mRNA COVID-19 vaccines

Development to begin immediately targeting vaccine availability in 2022


GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.GSK will also ...


image description
CureVac’s COVID-19 Vaccine Candidate Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection


CureVac N.V. announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 ...


Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE